# A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

> **NCT06088043** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 693 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** TAK-279
- **DRUG:** Placebo
- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT06088043
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-06
- **Primary completion:** 2025-01-22
- **Final completion:** 2025-10-22
- **Target enrollment:** 693 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088043, "A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06088043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*